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Background: Gastrointestinal surgery is associated with one of the highest rates of SSI due to the nature of
the surgery and to the added complication of operating on patients with signiﬁcant co-morbidities. This
high rate of SSI may negatively impact wound healing, patient recovery time, length of hospital stay and
associated healthcare costs. This article provides an overview of the efﬁcacy and safety of prophylactic
application of resorbable gentamicin-containing collagen implants (GCCI) in the prevention of SSI
following GI surgical procedures.
Method: Thirteen publications were identiﬁed using the PubMed online database and search terms
‘gentamicin collagen implant’ plus ‘surgical site infection’, ‘wound infection’ and ‘gastrointestinal
surgery’.
Results: Eleven out of 13 studies have demonstrated that prophylactic use of GCCI can reduce the wound
infection rate in high-risk GI surgical procedures (e.g. abdominoperineal resection [APR]) and improve
wound healing after pilonidal sinus excision. GCCI may also have a role to play in preventing anastomotic
leakage following mesorectal excision for rectal carcinoma. It is recommended that GCCI are used dry in
line with the manufacturer’s recommendations.
Conclusion: This review demonstrates that GCCI can signiﬁcantly reduce surgical site infection following
GI surgery including pilonidal sinus excision and high-risk procedures such as APR.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
This risk of a patient developing a surgical site infection (SSI)
following gastrointestinal (GI) surgery is relatively high compared
to other areas of surgery.1 A recently published Spanish study
reported the risk of a patient developing SSI following surgery for
colon cancer at 23%.2 By comparison the risk of SSI in a patient
undergoing hip arthroplasty has recently been reported by the UK
Health Protection Agency as being less than 1%.3 The heightened
risk of developing SSI in GI surgery is mainly due to the nature of
the procedure (i.e. often involving the bowel).1,4 Some of the higher
rates of SSI in GI surgery are associated with newer techniques
aimed at improving local control and resectability of the tumour
e.g. pre-operative radiotherapy followed by abdominoperineal
resection (APR).5,6 In a Dutch study SSI was reported in 29% of
patients who received neoadjuvant radiotherapy following APR
compared to 18% in the surgery alone group.5urgery, Maastadweg 21, 3079
358; fax: þ31 (0)10 2911043.
.J. de Bruin).
ciates Ltd. Published by Elsevier LtThe incidence of SSI following GI surgery is also increased in
high-risk patients such as those with co-existing conditions and
systemic disease.4,7 Data reported by the Health Protection Agency
(HPA) in the UK in 2006 demonstrated how the risk of SSI in
patients undergoing small bowel surgery rose from 8.1% in those
with no risk factors (NNIS risk score 0) to 24.4% in those with an
NNIS risk score of three.7 SSIs that develop following GI surgery
tend to bemore serious in type compared to other areas of surgery.7
In both small and large bowel procedures the percentage of deep
and organ space SSIs is much higher than in orthopaedic and
vascular procedures.8
The development of SSI in GI as well as other surgical proce-
dures has a negative impact on patient morbidity and mortality as
well as length of hospital stay and associated healthcare costs.7,8
Patients who developed an SSI following small bowel surgery in
England more than doubled their time spent in hospital compared
to those without SSI (25 days vs 11.5 days respectively).8 The extra
healthcare cost associated with the increase in length of hospital
stay (LOS) for these patients was estimated at £3836 per SSI.8
Therefore there is a need for better prevention of SSIs following
GI surgery in order to improve patient morbidity, reduce mortality
and decrease associated healthcare costs.d. All rights reserved.
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surgical technique is the use of antibiotic prophylaxis administered
systemically both pre and post-operatively.
However, following GI surgery there is a tendency to administer
systemic antibiotics for longer time periods despite the fact that
this may not necessarily lower the risk of SSI and this may in turn
lead to a greater risk of antibiotic resistance.9e12
The emergence of technologies such as resorbable gentamicin-
containing collagen implant (GCCI), which deliver high local
concentrations of gentamicin with corresponding low serum levels
offer both a means of lowering the risk of antibiotic resistance by
reducing the need for long-term administration of systemic anti-
biotics and also avoiding the toxicity of these regimens.13e15 The
use of GCCI also avoids the need for re-operation as the implant is
fully resorbable unlike polymer polymethylmethacrylate (PMMA)
beads which require subsequent removal. The use of collagen as
a carrier also has a positive effect on wound healing.16
Of speciﬁc relevance to SSI following GI surgery Binnebösel and
colleagues discovered that intra-abdominal applied gentamicin can
enhance the healing of anastomosis and increase the collagen
content en ratio of type I/III in a rat model.17 Junge et al. have
demonstrated that the quality of collagen formation was signiﬁ-
cantly increased when gentamicin was used to supplement a pol-
yvinylidenﬂouride mesh material used with the objective of
improving scar quality and mesh integration in hernia repair in
a rat model.18
A number of resorbable GCCI are available worldwide. The
objective of this article is to review the published clinical data for
prophylactic application of resorbable GCCI following GI surgery in
order to provide an overview of the efﬁcacy and safety of GCCI in
this indication with particular focus on high-risk procedures.
2. Methods
Candidate publications were identiﬁed using the National Institutes of Health
PubMed database for articles published between January 1990 and July 2011. Articles
were identiﬁed using the search terms ‘gentamicin-containing collagen implant’
plus ‘surgical site infection’, ‘wound infection’ and ‘gastrointestinal (GI) surgery’.
Reference lists of recent review articles were also scanned for additional citations.
The literature search was further supplemented by abstracts from international
Gastrointestinal Surgery congresses, which took place between January 2009 and
July 2011. Review publications were excluded from the analysis. The search identi-
ﬁed 13 potential publications focusing speciﬁcally on the prophylaxis of SSI in GI
surgery. These studies concerned the use of two GCCI i.e. Collatamp (EUSA Pharma
[Europe], Oxford, United Kingdom) and Septocoll (Biomet Deutschland GmbH,
Berlin, Germany). Collatamp contains gentamicin sulphate at a rate of 2 mg/cm.2 The
collagen in Collatamp is present at 2.8 mg/cm2 and is type I collagen from a rena-
tured bovine or equine source. Septocoll contains gentamicin sulphate (70 mg
gentamicin from 116 mg gentamicin sulphate base in 10 cm  8 cm implant) and
gentamicin crobefate (70 mg gentamicin from 350 mg gentamicin crobefate in
10 cm  8 cm implant). Septocoll contains type I collagen from a renatured equine
source.
The outcome measures of primary interest were SSI rate (superﬁcial and deep);
primary and secondary healing rate together with post-operative and surgical
complication rate. Other outcome measures include time to complete wound
healing; operating time; length of hospital stay; tumour recurrence (local and
distant); survival time; pain score; analgesic use and cost. The level of evidence for
each study was graded according to the criteria developed by Carruthers et al.193. Clinical experience
To date there have been 13 clinical studies which have focused
on the local application of GCCI in the prophylaxis of SSI following
GI surgery (Table 1). Seven studies were in what would be
considered procedures at high-risk of SSI and six in procedures at
medium-risk of SSI. Eleven of the studies were of randomised,
controlled design; one study included a consecutive patient series
with contemporaneous controls and one study included a consec-
utive patient series without contemporaneous controls. Nine of thestudies were graded as level 1.19 In total these studies represent
experience in n ¼ 915 patients treated prophylactically with GCCI
(n ¼ 815 with Collatamp and n ¼ 100 with Septocoll) following GI
surgery.
3.1. Rectal surgery
Five studies (n ¼ 588) (Table 1) have focused on use of GCCI plus
systemic antibiotics in the prophylaxis of SSI following high-risk GI
surgical procedures compared to systemic antibiotics alone.20e22,24,25
Four out of ﬁve of these studies have demonstrated that GCCI can
signiﬁcantly reduce wound infection rates, wound healing time and
lengthofhospital staycompared to standard treatmentwith systemic
antibiotics alone.
Rutten and colleagues ﬁrst described the use of GCCI in patients
undergoing a range of colorectal surgical procedures (Table 1).20
The use of GCCI signiﬁcantly lowered the rate of post-operative
wound infection by 13% compared to use of standard treatment
alone (p < 0.01). The difference between the two groups was
maintained even when patients with multiple complications were
excluded (p < 0.05). GCCI also shortened the length of hospital stay
by 2.5 days when compared to those administered systemic anti-
biotics alone. However, after exclusion of the patients with
complications unrelated to wound infection, the difference
between the two groups diminished, with the median stay in the
GCCI group being one day shorter than the standard treatment
group (13 vs 14 days respectively [n.s.]).
A second study of similar design22 reported a signiﬁcantly lower
post-operative complication rate in the GCCI group (at 30 days) in
all patients and also in those at higher risk of post-operative
complications i.e. in those whose surgery exceeded 3 h. This
study is the only analysis to report signiﬁcantly lower rates of
cancer recurrence (local or metastasis) and increased overall and
disease free survival (at 3 years) in the GCCI group. However, the
possible reasons for this difference between the two groups are
unclear.
Two further studies by Grüssner and colleagues and also by our
group focused speciﬁcally on patients undergoing APR of the ano-
rectum.21,24 In Grüssner’s analysis use of GCCI signiﬁcantly lowered
both the rate of perineal wound infections and secondary compli-
cations with infection by 15% compared to the use of standard
treatment alone. Furthermore the patients in the GCCI group had
a much greater reduction in the number of pathogens present in
post-operative wound secretion samples compared to the standard
treatment group.
The paper published in 2008 by our team was the ﬁrst to focus
on the effect of GCCI in patients undergoing APR following short-
term, neoadjuvant radiotherapy. All patients received pre-
operative radiation (5 Gy daily for 5 days) followed by APR using
the total mesorectal excision (TME) technique. Patients were then
treated with either GCCI; systemic antibiotics plus sacral drainage
(GCCI) or systemic antibiotics plus sacral drainage (standard
treatment) (Table 1).24 Similar to the results of the previously
mentioned studies our analysis demonstrated signiﬁcantly lower
rates of wound infection and higher rates of primary wound heal-
ing in those patients where GCCI was used as adjuvant treatment.
Use of GCCI also signiﬁcantly shortened themean length of hospital
stay by 10 days.
In 2010 Bennett-Guerrero and colleagues published the results
of a randomised study concerning the prophylactic use of GCCI with
systemic antibiotics versus standard treatment with systemic
antibiotics alone in patients undergoing open or laparoscopically
assisted colorectal surgery.25 In contrast to the four publications
described above this study did not demonstrate any beneﬁt of use
of GCCI. The patients in the standard treatment group had
Table 1
Overview of GCCI clinical publications in gastrointestinal surgery.
Author &
evidence
grading
Product Population Number of subjects and treatment groups Results
Rectal surgery
Rutten
(1997)20
Level 1
CollatampaImplant cut into three
longitudinal strips. The fascia was
closed & the implant placed directly
upon the closed fascia directly
adjacent to the surgical wound. The
skin was closed with a double layer
of resorbable sutures.
Patients stratiﬁed by type
of procedure
-Colonic resection
-Reversal of Hartmann procedure
-Abdominoperineal resection (APR)
-Subtotal colectomy
-Low anterior resection
n ¼ 221 total patients,
n ¼ 107 gentamicin-collagen implant
plus ceftriaxone þ metronidazole IV
or gentamicin þ metronidazole IV (Group I),
n ¼ 114 ceftriaxone þ metronidazole
IV or gentamicin þ metronidazole IV (Group II).
Wound infection:
Group I: 5.6% (6/107) vs
Group II: 18.4% (21/114) (p < 0.01).
LOS: Group I: 13.8 days vs Group II: 16.3 days (p ¼ 0.015).
Microbiology: Bacterial species were cultured from n ¼ 3/107
in Group I and n ¼ 8/114 in Group II.
Grüssner
(2001)21
Level 1
Septocoll
Three implants 5  8 cm evenly
inserted into the sacral cavity at one
level with the remnants of the M.
levator ani.
Patients undergoing
abdominoperineal
resection (APR) for low
rectal carcinoma
n ¼ 97 total patients
n ¼ 49 gentamicin collagen implant
plus cefazoline þ metronidazole plus
sacral drainage (Group I),
n ¼ 48 cefazoline þ metronidazole
plus sacral drainage (Group II).
Wound infection:
Group I: 3/49 vs Group II: 10/48 (p < 0.05).
Wound healing: Primary perineal wound healing e Group I:
43/49 vs Group II: 36/48 (n.s.).
Secondary perineal wound healing with infection e Group I:
3/49 vs Group II: 10/48 (p < 0.05).
Microbiology:
Bacteriologic efﬁcacy in Group I: 41/49 vs Group II: 29/48
(p ¼ 0.013).
Nowacki
(2005)22
Level 1
Collatamp
One 10  10 cm implant placed in
the pre-sacral area below the
peritoneal reﬂection. When anterior
resection was performed the
implant was wrapped around the
anastamosis.
Patients undergoing
-Anterior resection
-Low anterior resection
-Abdominoperineal
resection (APR)
-Hartmann procedure
n ¼ 229 total patients,
n ¼ 113 gentamicin collagen implant
plus metronidazole þ cefuroxamine
IV (Group I),
n ¼ 116 metronidazole þ cefuroxamine
IV (Group II).
Early post-operative complications (30 days): Total
complications in 218 evaluable patients e Group I:
20.7% (22/106) vs Group II: 37.5% (42/112) (p ¼ 0.0441).
Surgery > 3 h e Group I: 19.2% (15/78) vs Group II:
40.8% (31/76) (p ¼ 0.0314).
Intraoperative bowel perforation/ contamination of peritoneal
cavity e Group I: 20% (3/15) vs Group II: 57.9% (11/19)
(p ¼ 0.01).
Szynglarewicz
(2006)23
Level 5
Collatamp
Implant placed in the pre-sacral
area and wrapped around the
anastomosis.
Patients with rectal cancer
undergoing sphincter- preserving
total mesorectal excision without
defunctioning stoma
n ¼ 10 gentamicin collagen implant There was no anastamotic leak and no septic complications
in all 10 patients.
de Bruin
(2008)24
Level 3
Collatamp
Three implants inserted into the
sacral wound cavity at one level
with the remnants of the musculus
levator ani.
Consecutive series of
patients undergoing
abdominoperineal
resection (APR) for
rectal cancer after
short-course radiotherapy
n ¼ 40 total patients,
n ¼ 19 gentamicin collagen implant plus
amoxicillin þ clavulanate IV plus sacral
drainage (Group I),
n ¼ 21 amoxicillin þ clavulanate IV plus
sacral drainage (Group II).
Wound infection:
Total wound infection (deep & superﬁcial) - Group I: 3/19 vs
Group II: 12/21 (p ¼ 0.01).
Deep wound infection e Group I: 1/19 vs Group II: 6/21
(p ¼ 0.05). Superﬁcial wound infection e Group I: 2/19 vs
Group II: 6/21 (n.s.).
Wound healing: Primary wound healing e Group I: 16/19 vs
Group II: 9/21 (p < 0.01).
LOS: Group I: 15 days vs Group II: 25 days (p ¼ 0.04).
Bennett-
Guerrero
(2010)25
Level 1
Collatamp
Two implants placed anteriorly to
the fascia along the full length of the
incision. To facilitate placement the
implants could be cut into strips
while dry.
Patients undergoing
open or laparoscopically
assisted colorectal surgery
n ¼ 602 total patients,
n ¼ 300 gentamicin collagen implant plus
prophylactic antibiotics (Group I),
n ¼ 302 prophylactic antibiotics (Group II).
Prophylactic antibiotics included one of the
following regimens e cefazolin þ metronidazole,
cefoxitin or ciproﬂoxacin þ clindamycin or
metronidazole for maximum 24 h. Oral
antibiotics could be added to the prophylactic
regimen e oral neomycin or oral metronidazole.
Wound infection: Total wound infection (deep & superﬁcial)
at 60-day follow-up e Group I: 30% (n ¼ 90/300) vs Group II:
20.9% (n ¼ 63/302) (p ¼ 0.01). Deep wound infection e Group I:
8.3% (n ¼ 25/300) vs Group II: 6.0% (n ¼ 18/302) (n.s.).
Superﬁcial wound infection e Group I: 20.3% (n ¼ 61/300) vs
Group II: 13.6% (n ¼ 41/302) (p ¼ 0.03).
LOS: Group 1: 6.0 days (5.0e8.0) vs Group II:
6.0 days (4.0e8.0) (n.s.).
Re-hospitalisation: Group I: 7.0% (n ¼ 21) vs Group II:
4.3% (n ¼ 13) (n.s.).
Complications: Percentage of patients visiting a hospital
emergency department or physician with wound-related
signesymptom Group I: 19.7% (n ¼ 57/302) vs Group II:
11.0% (n ¼ 31/300) (p ¼ 0.004).
(continued on next page)
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Table 1 (continued )
Author &
evidence
grading
Product Population Number of subjects and treatment groups Results
Abdominal surgery
Gomez
(1999)26
Level 1
Collatamp
One 10  10 cm implant placed in
the wound above the aponeurosis &
the wound sutured.
Patients with ‘dirty’
abdominal wounds
derived from lower
GI tract surgery e.g.
colon perforation, acute
appendicitis or gallbladder
perforation
n ¼ 66 total patients,
n ¼ 34 gentamicin collagen implant plus
metronidazole IV for 7 days plus primary
closure (Group I),
n ¼ 32 open wound cleaned daily with
povidone solution plus metronidazole þ
gentamicin IV for 7 days. The wound was
closed after 3 days if no infection (Group II).
Wound infection: Group I: 3/34 vs Group II: 14/32 (p < 0.001).
Wound healing: Group I: 10.31 days vs Group II: 15.20 days
(p < 0.001).
LOS: Group I: 5.45 days vs Group II: 7 days.
Microbiology: Group I had mono-microbial wound infections
whereas Group II had multi-microbial wound infections.
Haase (2005)27
Level 2
Collatamp
One implant placed subcutaneously
& the wound sutured.
Patients undergoing
loop-ileostomy closure
n ¼ 80 total patients,
n ¼ 40 gentamicin collagen implant (Group I),
n ¼ 40 collagen implant without gentamicin
(Group II).
Wound infection: There was no statistical difference in the rate
of wound infection between the two groups (4/40 vs 4/40). The
infection rate in both groups was much lower than previously
reported with this type of procedure.
Surgical complications:
There was no statistical difference in the rate of surgical
complications between the two groups.
Pilonidal sinus repair
Vogel
(1992)28
Level 1
Collatamp
Wound covered with 1e4 implants
according to the size of the excision
and the wound closed with 1e2 layers
of sutures.
Patients undergoing
surgical excision for
pilonidal sinus
n ¼ 80 total patients,
n ¼ 40 gentamicin collagen implant plus
extensive excision of pilonidal sinus (Group I),
n ¼ 40 extensive excision of pilonidal sinus
(Group II).
Wound healing: Primary healing rate e Group I: 35/40 vs
Group II: 14/40 (p < 0.001).
Secondary wound healing e Group I: 5/40 vs Group II:
25/40 (p < 0.001).
Abscesses led to secondary wound healing in 3/40 in
Group I vs 20/40 in Group II (p < 0.001).
On follow-up examination at one year no recurrence had
occurred in either group.
Holzer (2003)29
Level 1
Septocoll
One 5  8 cm implant implanted in
the wound cavity. The wound was closed
with 1e2 layers of sutures after placement
of a drain.
Patients undergoing
surgical excision
for pilonidal sinus
n ¼ 103 total patients
n ¼ 51 gentamicin collagen implant plus
primary closure (Group I)
n ¼ 52 open treatment (Group II)
Wound healing: Time to complete wound healing e Group I:
17 days vs Group II: 68 days (p ¼ 0.0001).
LOS: Group I: 9 (1e24) days vs Group II: 10 (1e13) days.
One recurrent pilonidal sinus was seen in Group I and none
in Group II during the 26-week follow-up period.
Rao (2010)30
Level 1
Collatamp
One to two implants were inserted
depending on size of cavity. The wound was
closed with two layers of sutures.
Patients undergoing
surgical excision
for pilonidal sinus
n ¼ 60 total patients,
n ¼ 30 gentamicin collagen implant plus
primary closure (Group I),
n ¼ 30 open treatment (Group II).
Wound healing: Percentage patients healed after 4 weeks e
Group I: 27/30 vs Group II: 4/30 (p < 0.001).
Mean time to wound healing e Group I: 10 days vs Group II:
50 days (p < 0.001).
LOS: There was no difference seen between the two groups in
length of hospital stay.
Andersson (2010)31
Level 2
Collatamp
The implant was inserted into the cavity
left by the excision. The wound was closed
with one layer of sutures.
Patients undergoing
surgical excision
for pilonidal sinus
n ¼ 159 total patients
n ¼ 82 gentamicin collagen implant (Group I)
n ¼ 77 no adjuvant treatment (Group II)
Wound infection: Percentage of patients with infection at 2
weeks follow-up Group I: 22% (n ¼ 18/82) vs Group II:
26% (20/77) (n.s.). Percentage patients with infection at
3 mths follow-up Group I: 2% (n ¼ 2/82) vs Group II: 0% (n.s.).
Wound healing: Percentage patients healed at 3 mths follow-up
Group I: 77% (n ¼ 63/82) vs Group II: 66% (n ¼ 51/77) (n.s.).
Percentage patients healed at 1 year follow-up Group I: 85%
(n ¼ 70/82) vs Group II: 90% (n ¼ 69/77) (n.s.).
Nine patients in each group had remaining symptoms of
pilonidal sinus at 1-year follow-up. Re-operations took place in
eight patients (10%) in Group I and 3 patients (4%) in Group II.
Yetim (2010)32
Level 1
Collatamp
One implant was inserted in the sacral fascia.
The wound was closed with two layers
of sutures.
Patients undergoing
surgical excision
for pilonidal sinus
n ¼ 80 total patients,
n ¼ 40 gentamicin collagen implant (Group I),
n ¼ 40 oral antibiotics for 7 days (1 g/day
oral ciprofoxacin and ornidazole combination)
(Group II).
Wound healing: Percentage patients healed at follow-up
Group I: 38/40 vs Group II: 32/40 (p < 0.001). Mean time to
wound healing e Group I: 8.85 days (0.8) vs Group II:
15.1 days (1.1) days (p < 0.001).
LOS: Group I: 2.02 (0.6) days vs Group II: 4.28 (0.8) days
(p < 0.001). Six recurrent pilonidal sinus were seen in Group
II but none were seen in Group I (p < 0.001).
a Also known as Collatamp EG, Collatamp G Cronocol, Duracoll Implant, Garacol, Garacoll, Garacoll Implant, Garamacin Pads, Garamycin, Garamycin Schwamm, Gentacoll, Gentacoll Implant, Gentalyn,
Gentimplant, Sulmycin, Sulmycin Implant E Schwamm, Sulmycin Implant Schwam.
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ORIGINAL RESEARCHa signiﬁcantly lower rate of wound infection (superﬁcial and deep)
and superﬁcial infection together with fewer wound-related
complications requiring an emergency department visit
compared to those in the GCCI group. There was no statistical
difference seen between the two groups in rate of deep wound
infection, mean length of hospital stay or the rate of re-
hospitalisation due to SSI. The frequency of adverse events did
not differ signiﬁcantly between the two groups.
GCCI have also been utilised to prevent anastomotic leakage
following surgery. In a small consecutive series of 10 cases under-
going sphincter preserving TME for rectal cancer all patients
received systemic antibiotics plus GCCI (Table 1).23 The anasta-
moses were wrapped with GCCI applied deeply into the pre-sacral
area to the levators level. A further 1e3 GCCI were formed and
pressed to the bowel wall. Neither clinically anastomotic symp-
tomatic leakage nor any other septic complications were reported
in this small patient series.
3.2. Abdominal surgery
Two studies have assessed the effect of the prophylactic appli-
cation of GCCI in high-risk abdominal surgery. In 1999 Gomez and
colleagues published the results of a study comparing the use of
GCCI plus systemic antibiotics and primary wound closure with use
of systemic antibiotics and an open wound technique for the
prophylaxis of infection in high-risk, ‘dirty’ abdominal wounds (e.g.
through colon perforation) (Table 1).26 The use of GCCI prior to
wound closure lowered the wound infection rate by 34% compared
to use of systemic antibiotics and an open wound technique. A
signiﬁcant beneﬁt of use of GCCI was also seen in reducing the time
to wound healing by 5 days.
A second, randomised study focused speciﬁcally on the effect of
GCCI on the incidence of wound infection following loop-ileostomy
closure (Table 1).27 Eighty patients were randomised to application
of GCCI or identical collagen implant without gentamicin. There
was no statistical difference in the rate of wound infections or
surgical complications between the two groups. The infection rate
in both groups was much lower than previously reported with this
type of procedure.33e35
3.3. Pilonidal sinus excision
Five randomised studies have assessed the effectiveness of GCCI
in patients undergoing excision of pilonidal sinus with primary
closure of the wound.28e32 Vogel and colleagues found that the
primary healing rate was signiﬁcantly higher with GCCI, with over
twice the number of patients having healed post-operatively
compared to those who did not have GCCI inserted prior to
wound closure (Table 1).28 The GCCI patients also had a signiﬁ-
cantly lower secondary healing rate overall. Furthermore less than
10% of the patients had post-operative abscess formation in the
GCCI group, in contrast with over half of the patients in the non-
GCCI group. On follow-up examination at one year no recurrence
had occurred in either group.
The second randomised study in the excision of pilonidal sinus
compared use of GCCI plus primary closure to open treatment, in
order to compare surgical techniques for this indication.29 In the
GCCI group 14/51 (27%) patients failed to achieve primary healing.
Five of these required a conversion to open treatment and nine
underwent spontaneous dehiscence. Thus overall 37/51 (73%)
patients experienced primary healing at 2 weeks. The median time
to complete wound healing was signiﬁcantly shorter in the GCCI
group compared to the open procedure group. Patients in the open
procedure group took almost four times as long to heal compared to
the patients in the GCCI group. Despite the longer healing time seenin the open group there was no signiﬁcant difference between the
two groups in mean length of hospital stay. One recurrent pilonidal
sinus was seen in the GCCI group and none in the open group in the
26-week follow-up period.
In a study of similar design Rao and colleagues followed patients
to assess recurrence rates at 5 years.30 Signiﬁcantly more patients
in the GCCI group had healed completely compared to those in the
open group at four weeks. Furthermore the wounds in the GCCI
group healed 40 days faster compared to those in the open group.
The patients in the GCCI group experienced signiﬁcantly less pain
on days 2, 4 and 7 post-operation (as reﬂected by their linear
analogue pain scores) compared to the patients in the open group.
The closed wounds in the GCCI group required signiﬁcantly fewer
dressings (mean of 2) compared to the open wounds (mean of 25).
There was no difference seen between the two groups in length of
hospital stay.
Despite the lack of difference seen in length of hospital stay
between the two groups the overall cost per patient (calculated as
hospital stay, cost of materials e.g. dressings and district nursing
costs)was signiﬁcantly lower for patients in theGCCI group (meanof
£149) compared to those in the open group (mean of £660). Recur-
rence rates were similar at the 5-year follow-up for both groups.
The results of a study published in 2010 by Andersson and
colleagues did not show any beneﬁt of GCCI plus primary closure in
reducing the rate of wound infection, wound healing, and recur-
rence when compared to primary closure alone (Table 1).31
A study in 80 patients who underwent excision plus primary
closure compared adjuvant use of GCCI to that of oral antibiotics
(Table 1).32 Similar to the studies of Vogel, Holzer and Rao
a signiﬁcant beneﬁt of GCCI was demonstrated in the percentage of
wounds healed at follow-up. GCCI also shortened the mean time to
wound healing by six days. Unlike the other pilonidal studies the
patients in the GCCI group also spent signiﬁcantly less time in
hospital and had a lower recurrence rate compared to those
administered oral antibiotics.
4. Discussion
Data from national and regional surveys and single studies have
highlighted high SSI rates following GI surgical procedures.
Furthermore it has been estimated that almost one third of patients
may develop an SSI following newer surgical techniques such as
APR combined with neoadjuvant radiotherapy. Studies have
established that SSIs have a negative impact on morbidity,
mortality and healthcare costs following GI surgery and therefore
there is a need for more effective preventive measures. Unfortu-
nately, there is a lack of evidence for prolonged use of prophylactic
systemic antibiotics in reducing the SSI rate in GI surgery and this
approach may also lead to antibiotic resistance. However, in 1997
Rutten and colleagues demonstrated the efﬁcacy of locally applied
gentamicin and its ability to lower the risk of post-operativewound
infection with a combined treatment strategy (resorbable
implant þ systemic antibiotics).
The majority of the studies included in this review have
demonstrated that GCCI can reduce the wound infection rate and
accelerate wound healing following GI surgery compared to stan-
dard treatment. Importantly GCCI can also positively inﬂuence the
post-operative course and length of hospital stay for patients
undergoing particularly risky procedures e.g. APR combined with
neoadjuvant radiotherapy. The review also supports the use of GCCI
and primary closure in patients undergoing pilonidal sinus excision.
GCCI improved thewound infection rate, shortened the time it took
for wounds to heal and also prevented recurrence. These results can
have positive implications for healthcare providers by reducing the
length of hospital stay and associated healthcare costs.
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ORIGINAL RESEARCHOf the 13 studies reviewed three did not show any signiﬁcant
beneﬁt of local application of GCCI. In contrast to the four positive
publications in colorectal surgery the study by Bennett-Guerrero
and colleagues did not demonstrate any beneﬁt of use of GCCI
over standard treatment. The authors have put forward a combi-
nation of factors that they think may go someway to explaining the
lack of beneﬁt seen in the GCCI group including differences in
reporting and patient population between this study and the other
positive colorectal studies. One important difference which the
authors do not highlight is the fact that the protocol for the
Bennett-Guerrero study required that the implants be wetted in
saline prior to implantation.36 The effect of the wetting of the
implants has been researched by Lovering and colleagues and they
have shown that there is loss of gentamicin into the saline solution
prior to insertion of the implant and this in turn may result in
leaching of gentamicin into the surrounding tissues and ﬂuids,
resulting in modiﬁed kinetics of gentamicin release after implan-
tation.37 This attenuates the initial peak in gentamicin concentra-
tion at the surgical site that is required for efﬁcacy against
gentamicin-resistant organisms.37 The manufacturer’s recommen-
dation is that GCCI should be used dry prior to implantation.38
Haase et al. showed no additional beneﬁt of GCCI in reducing
wound infection rate following loop-ileostomy closure. However,
the study did have an extremely low SSI rate in the control group
(10%) in contrast to that seen in the literature (up to 41% of
patients).33e35,39,40
The results of the study published in 2010 by Andersson and
colleagues did not show any beneﬁt of GCCI and open closure
compared to open closure alone in patients undergoing pilonidal
excision. The lack of beneﬁt may be explained by the difference in
closure technique used. Andersson closed the wound using
a midline closure technique and one layer of skin sutures whereas
in the studies of Vogel, Rao and Yetim the wounds were closed
using an ‘off-midline’ technique or a combination of one to two
layers of subcutaneous sutures and one layer of skin sutures.
Several studies have reported on the complications (tissue tension
etc) associated with the midline closure technique.41,42
This review of the efﬁcacy of GCCI has highlighted several topics,
which may have positive implications for a range of GI surgical
procedures and warrant further investigation. The data in mouse
models published by Binnebösel and Junge suggest there is a posi-
tive effect of local gentamicin on collagen content and metabolism.
However, there has been conﬂicting data published on the
subject.43 Therefore further work is required in patients to discover
the mechanism involved and the implications for GCCI use.
Studies are also required to evaluate the health economic
beneﬁt of GCCI in GI surgery. The clinical data reviewed here has
demonstrated a positive effect on length of hospital stay with GCCI
following rectal tumour resection. In the published study from our
group the difference in the length of hospital stay between the two
groups was 10 days and this may indicate a potentially large saving
in hospital costs per patient treated prophylactically with GCCI
following APR. Furthermore overall costs were shown to be
signiﬁcantly reduced with GCCI following excision of pilonidal
sinus in a relatively small study. However, there has been no study
to date which has utilised health economic endpoints in order to
prospectively analyse the potential direct and indirect costs savings
with GCCI in high-risk GI surgical procedures.
5. Conclusion
This review demonstrates that when used dry prior to insertion
GCCI can be effective in reducing surgical site infection following GI
surgery including pilonidal sinus excision and high-risk procedures
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